Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Amplia Therapeutics ( (AU:ATX) ) has provided an announcement.
Amplia Therapeutics has announced that its ACCENT trial, which evaluates the combination of its FAK inhibitor narmafotinib with standard chemotherapies gemcitabine and Abraxane, has achieved a key milestone with 15 confirmed partial responses in patients with advanced pancreatic cancer. This demonstrates the superiority of the combination therapy over chemotherapy alone, potentially enhancing the company’s positioning in the oncology market. The trial’s success could have significant implications for stakeholders, as it suggests a promising new treatment option for a highly aggressive cancer type.
More about Amplia Therapeutics
Amplia Therapeutics Limited is an Australian pharmaceutical company focusing on the development of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company has a particular emphasis on fibrotic cancers such as pancreatic and ovarian cancer, and FAK is also a significant target in chronic diseases like idiopathic pulmonary fibrosis.
Average Trading Volume: 387,584
Technical Sentiment Signal: Sell
Current Market Cap: A$21.34M
Find detailed analytics on ATX stock on TipRanks’ Stock Analysis page.